


**ISSC 2023  
Committee Report**

**Committee Name :** Plant Evaluation Criteria  
**Chairperson:** Joel Hansel  
**Date of Meeting:** 2020-2022  
**Recorder:**

**Approved**  
**By:**   
**Printed Name:** Joel Hansel  
Shannon Jenkins  
(Substitute Chair)

**Committee Members Present:**

<input type="checkbox"/> Joel Hansel (Chairperson)	<input checked="" type="checkbox"/> Kirk Wiles	<input type="checkbox"/> Virginia Wheatley	(FDA Delegate)
<input checked="" type="checkbox"/> Shannon Jenkins	<input checked="" type="checkbox"/> Kim Stryker	<input checked="" type="checkbox"/> Danielle Schools	<input checked="" type="checkbox"/> David Wiggins (FDA Advisor)
	<input type="checkbox"/> Eric Hickey	<input checked="" type="checkbox"/> Raymond Burditt	

---

**Charges**

**Charge 1: Proposal 19-305: Evaluation of Shellfish Sanitation Program Elements.**

Findings/Conclusions:

Committee met in 2020 and worked on the in-field criteria that FDA uses. The Executive board gave interim approval for proposal 19-310 which will be voted on for full approval at this conference.

Bess Ormond provided that FDA has compared state performance from the past to see how they would fair with the new criteria. During 2020 and 2021 the infield criteria could not be used because of the COVID pandemic, but it was used in 2022. FDA looked back from 2016 to 2021 and compared state performance and found that state compliance trended upward. Most states from 2021 were in conformance, some raised from provisional conformance. Comparison was not shared with individual states, but FDA is happy to do that on a state-by-state basis.

Recommendations:

19-305 was originally referred to the Regulatory Relations, but that committee was dissolved, and this proposal was transferred to Plant Evaluation Criteria Committee.

Raymond Burditt made a motion to recommend no action be taken on this proposal (19-305) and Eric Hickey seconded. Rationale is that it is not appropriate MO language and that FDA Specialists are already instructed to work with each state to figure out what works best for them. **MOTION WAS APPROVED**

Kirk Wiles made a motion that the committee recommend that FDA consult with states and seek permission for FDA specialist standardization at the same time. Seconded by Raymond Burditt. **MOTION WAS APPROVED**

**Charge 2: Proposal 19-310: Plant Element Evaluation Criteria.**

Findings/Conclusions:

19-310 had an interim action and it is referred to General Assembly at this conference.

Recommendations:

19-310 had an interim action and it is referred to General Assembly at this conference.

**Charge 3: Proposal 19-311: NSSP Plant and Shipping Evaluation Criteria.**

Findings/Conclusions:

Recommendations:

Kirk Wiles made a motion to recommend no action on 19-311, seconded by David Wiggins. Rationale is that there has been progress made through proposal 19-310 so this is no longer necessary. **MOTION WAS APPROVED**

**Charge 4: Proposal 19-312: Plant and Shipping Element Evaluation Criteria.**

Findings/Conclusions:

Recommendations:

Raymond Burditt made a motion that PECC recommend that Task Force III refer proposal 19-312 to an appropriate committee. Eric Hickey seconded. **MOTION WAS APPROVED**